0001910175-22-000001.txt : 20220210 0001910175-22-000001.hdr.sgml : 20220210 20220210134728 ACCESSION NUMBER: 0001910175-22-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220210 DATE AS OF CHANGE: 20220210 EFFECTIVENESS DATE: 20220210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Indapta Therapeutics Inc. CENTRAL INDEX KEY: 0001910175 IRS NUMBER: 814700988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-433098 FILM NUMBER: 22612958 BUSINESS ADDRESS: STREET 1: 5000 MONTROSE BLVD. CITY: HOUSTON STATE: TX ZIP: 77006 BUSINESS PHONE: 917-282-9768 MAIL ADDRESS: STREET 1: 5000 MONTROSE BLVD. CITY: HOUSTON STATE: TX ZIP: 77006 D 1 primary_doc.xml X0708 D LIVE 0001910175 Indapta Therapeutics Inc. 5000 MONTROSE BLVD. HOUSTON TX TEXAS 77006 917-282-9768 DELAWARE None None Corporation true Mark Frohlich 5000 Montrose Blvd. Houston TX TEXAS 77006 Executive Officer Director Ronald Martell 5000 Montrose Blvd. Houston TX TEXAS 77006 Director Lori Hu 5000 Montrose Blvd. Houston TX TEXAS 77006 Director Laura Stoppel 5000 Montrose Blvd. Houston TX TEXAS 77006 Director Fabio Pucci 5000 Montrose Blvd. Houston TX TEXAS 77006 Director Guy DiPierro 5000 Montrose Blvd. Houston TX TEXAS 77006 Executive Officer Other Technology Decline to Disclose 06b false 2022-01-28 false true true false 0 67132102 33603097 33529005 Total Offering Amount and Total Amount Sold includes $7,132,102.32 in connection with the conversion of convertible promissory notes. false 37 2400000 true 0 0 false Indapta Therapeutics Inc. /s/ Mark Frohlich Mark Frohlich Chief Executive Officer 2022-02-09